Evidence map›Paper›PMID 39266951›Full record

SynthesisBMC anesthesiology2024

The role of esmolol in sepsis: a meta-analysis based on randomized controlled trials.

Ya Wei, Fengshan Bo, Jiakai Wang, Jianyu Fu, Yuyang Qiu, Hongying Bi, Dehua He, Xu Liu

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC anesthesiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ya Wei *Department of Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, 550001, China.
Fengshan Bo *Department of Anesthesiology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, 264000, China.
Jiakai WangDepartment of Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, 550001, China.
Jianyu FuDepartment of Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, 550001, China.
Yuyang QiuDepartment of Emergency Intensive Care Unit, Affiliated Jinyang Hospital of Guizhou Medical University, Guiyang, Guizhou, 550081, China.
Hongying BiDepartment of Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, 550001, China.
Dehua HeDepartment of Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, 550001, China.
Xu LiuDepartment of Critical Care Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, 550001, China. 262347762@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSepsis is associated with a high incidence and mortality and poses a significant challenge to the treatment. Although esmolol has shown promise in sepsis treatment, its efficacy and safety remain contentious. This meta-analysis aims to clarify the role of esmolol in sepsis management.

methodsPubMed, Embase, Web of Science, Cochrane library, clinicaltrials.gov and the Chinese Clinical Trial Registry were searched and references of relevant reviews and meta-analysis were also screened for appropriate studies. Keywords and free words of 'sepsis', 'esmolol' and 'randomized controlled trials' were used for search. Meta-analysis was performed using RevMan 5.3 software.

resultsFifteen studies involving 1100 patients were included. Compared with the control group, patients receiving esmolol exhibited significantly decreased 28-day mortality (RR, 0.69; 95% CI, 0.60 to 0.81; P < 0.0001), heart rate (HR) (SMD, -1.15; 95% CI, -1.34 to -0.96; P < 0.0001), cardiac troponin I levels (cTnI) (SMD, -0.88; 95% CI, -1.13 to -0.64; P < 0.0001), length of intensive care unit (ICU) stay (SMD, -0.46; 95% CI, -0.62 to -0.3; P < 0.0001) and duration of mechanical ventilation (SMD, -0.28; 95% CI, -0.48 to -0.09; P = 0.004) and significantly increased central venous oxygen saturation (ScvO

conclusionEsmolol reduces 28-day mortality, length of ICU stay and duration of mechanical ventilation in sepsis patients. Furthermore, esmolol improves oxygen metabolism, mitigates myocardial injury and decreases heart rate without significantly affecting hemodynamic parameters.

trial registrationThis study was registered on the PROSPERO website (registration number: CRD42023484884).

Indexed as

Adrenergic beta-1 Receptor AntagonistsPropanolaminesSepsisHeart RateHumansLength of StayRandomized Controlled Trials as TopicAdrenergic beta-1 Receptor AntagonistsesmololPropanolaminesEsmololMeta analysisRandomized controlled trialsSepsisSeptic shock

Identifiers

PMID39266951
PMCPMC11391746

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.